Presbia PLC, an ophthalmic device company, has appointed Dr. Gerd Auffarth to its Board of Directors and Dr. Mark Blumenkranz to its Medical Advisory Board. Dr. Auffarth is the director of the International Vision Correction Research Center and the David J. Apple International Laboratory for Ophthalmic Pathology. He conducts research in corneal surgery, presbyopia, cataracts and intraocular lens implants, and has expertise in IOLs, multi- focal IOLs, refractive laser technologies and presbyopia surgery. He has a doctorate from Aachen University of Technology. Dr. Blumenkranz is the H.J. Smead Professor in the Department of Ophthalmology at Stanford University. He received his bachelor’s and doctorate degrees from Brown University and completed his fellowship in vitreoretinal diseases at the Bascom Palmer Eye Institute in Miami. He transitions to the Medical Advisory Board from the Board of Directors. “We thank Dr. Blumenkranz for his prior service and continuing involvement through the Presbia Medical Advisory Board. It is an honor to have Dr. Auffarth on our Board of Directors,” said Randy Thurman, chairman of the board. “His decision to join underscores our goal of Presbia’s Microlens to meet the needs of millions of presbyopic patients worldwide. His reputation is not only well-established throughout Europe, but his leadership in South Korea and other Asian countries aligns perfectly with our commercialization strategy.” For more information, visit: www.presbia.com.